Protalix BioTherapeutics Inc 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGEACT OF 1934 Forthe quarterly period ended March31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGEACT OF 1934 For the transition period fromto001-33357(Commission file number) PROTALIX BIOTHERAPEUTICS,INC.(Exact name of registrant as specified in its charter) Delaware__65-0643773__(State or other jurisdictionof incorporation or organization)(I.R.S. EmployerIdentification No.)2 University PlazaSuite 100Hackensack, NJ07601(Address of principal executive offices)(Zip Code)(201)-696-9345(Registrant’s telephone number, including area code)N/A(Former name, former address and former fiscalyear, if changed since last report)Securities registered pursuant to Section12(b)of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of the Securities Exchange Act of1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to suchfiling requirements for the past 90days. Yes⌧No◻ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405of Regulation S-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant was required to submitsuch files). Yes⌧No◻ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule12b-2 of the Exchange Act: If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.◻ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No☒On May1, 2026, approximately 80,571,642 shares of the Registrant’s common stock, $0.001 par value, were outstanding. FORM 10-QTABLE OF CONTENTS PART I – FINANCIAL INFORMATION Item1.Financial StatementsCondensed Consolidated Balance Sheets (Unaudited) – As of March31, 2026 and December31, 20252Condensed Consolidated Statements of Operations (Unaudited) – For the Three Months EndedMarch31, 2026 and 20253Condensed Consolidated Statements of Changes inStockholders’ Equity(Unaudited) – For the ThreeMonths Ended March31, 2026 and 20254Condensed Consolidated Statements of Cash Flows (Unaudited) – For the Three Months EndedMarch31, 2026 and 20255Notes to Condensed Consolidated Financial Statements7Item2.Management’s Discussion and Analysis of Financial Condition and Results of Operations13Item3.Quantitative and Qualitative Disclosures About Market Risk21Item4.Controls and Procedures22PART II – OTHER INFORMATIONItem1.Legal Proceedings23Item1A. Risk Factors23Item2.Unregistered Sales of Equity Securities and Use of Proceeds23Item3.Defaults Upon Senior Securities23Item4.Mine Safety Disclosures23Item5.Other Information23Item6.Exhibits23Signatures25 PARTI– FINANCIAL INFORMATION PROTALIX BIOTHERAPEUTICS,INC.CONDENSED CONSOLIDATED BALANCE SHEETS(U.S. dollars in thousands)(Unaudited) March31,2026December31,2025 STOCKHOLDERS’ EQUITY67,22948,230Total liabilities and stockholders’ equity$102,336$82,346 PROTALIX BIOTHERAPEUTICS,INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(U.S. dollars in thousands, except share and per share data)(Unaudited) Three Months EndedMarch31,2026March31,2025REVENUES FROM SELLING GOODS$7,419$9,995REVENUES FROM LICENSE AND R&D SERVICES26,331118TOTAL REVENUE33,75010,113COST OF REVENUES(4,127)(8,180)RESEARCH AND DEVELOPMENT EXPENSES(5,426)(3,475)SELLING, GENERAL, AND ADMINISTRATIVE EXPENSES(3,051)(2,603)OPERATING INCOME (LOSS)21,146(4,145)FINANCIAL EXPENSES(193)(6)FINANCIAL INCOME188419FINANCIAL INCOME (EXPENSES), NET(5)413INCOME (LOSS) BEFORE TAXES ON INCOME21,141(3,732)TAXES ON INCOME (TAX BENEFIT)2,824(113)NET INCOME (LOSS)$18,317$(3,619)EARNINGS (LOSS) PER SHARE OF COMMON STOCK:BASIC$0.23$(0.05)DILUTED$0.22$(0.05)WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCKUSED IN COMPUTING EARNINGS (LOSS) PER SHARE:BASIC79,848,89276,611,980DILUTED83,048,59676,611,980 PROTALIX BIOTHERAPEUTICS,INC.CONDENSED CONSOLIDATED STATEMENTS OF CHANGES INSTOCKHOLDERS’ EQUITY(U.S. dollars in thousands, except share data) (Unaudited) The accompanying notes are an integral part of the condensed consolidated financial statements. PROTALIX BIOTHERAPEUTICS,INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(U.S. dollars in thousands) PROTALIX BIOTHERAPEUTICS,INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(U.S. dollars in thousands)(Unaudited) Purchase of property and equipme